| Combination of | |
|---|---|
| Hydrocodone | Opioid agonist |
| Homatropine | Muscarinic antagonist |
| Clinical data | |
| Trade names | Tussigon, Hycodan, Hydromet, others |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Hydrocodone/homatropine, sold under the brand name Tussigon among others, is a fixed-dose combination medication used for the treatment of cough.[1][2] It contains hydrocodone, as the bitartrate, an opioid agonist; and homatropine, as the methylbromide, a muscarinic antagonist.[1][2] It is taken by mouth.[1][2]
Hydrocodone/homatropine was approved for medical use in the United States in 1943.[1][2]
Adverse effects
In the US, the label for hydrocodone/homatropine contains a black box warning about addiction, abuse, and misuse.[1][2]
References
- ^ a b c d e f "Hycodan- hydrocodone bitartrate and homatropine methylbromide tablet; Hycodan- hydrocodone bitartrate and homatropine methylbromide solution". DailyMed. 29 December 2021. Retrieved 23 December 2023.
- ^ a b c d e f "Hydromet- hydrocodone bitartrate and homatropine methylbromide solution". DailyMed. 30 September 2022. Retrieved 23 December 2023.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 23 December 2023, at 08:42